InsidersTradesSigma
Follow the Avalyn Pharma Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Market capitalisation: €1.4bn. The latest transaction was reported on 5 May 2026 (C). Among the most active insiders: FMR LLC. The full history is accessible without an account.
Analysts rate Avalyn Pharma Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$59.00.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
7 of 7 declarations
Avalyn Pharma Inc. is a biopharmaceutical company focused on developing treatments for pulmonary diseases. It is listed on NASDAQ under the ticker AVTX.